From Human Megakaryocytes to Platelets: Effects of Aspirin on High-Mobility Group Box 1/Receptor for Advanced Glycation End Products Axis

• Main Authors: Stefania Mardente, Emanuela Mari, Isabella Massimi, Marco Tafani, Raffaella Guerriero, Ornella Morsilli, Fabio M. Pulcinelli, Marco E. Bianchi, Alessandra Zicari
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2018-01-01
• Series: Frontiers in Immunology
• Subjects: aspirin; platelets; megakaryocytes; high-mobility group box 1; receptor for advanced glycation end products
• Online Access: http://journal.frontiersin.org/article/10.3389/fimmu.2017.01946/full

Platelets (PLTs) are the major source of high-mobility group box 1 (HMGB1), a protein that is involved in sterile inflammation of blood vessels and thrombosis. Megakaryocytes (MKs) synthesize HMGB1 and transfer both protein and mRNA into PLTs and PLT-derived microvesicles (MV). Free HMGB1 found in supernatants of in vitro differentiated MKs and in a megakaryoblastic cell line (DAMI cells). Aspirin “in vivo” and “in vitro” not only reduces HMGB1 and receptor for advanced glycation end products expression on MKs and PLTs but also drives the movement of HMGB1 from MKs into PLTs and PLT-derived MV. These findings suggest that consumption of low doses of aspirin reduces the risk of atherosclerosis complications as well as reducing PLT aggregation by the inhibition of COX-1.